Uncategorized
Aerie reports fourth quarter net loss of $29.3 million
Aerie Pharmaceuticals reported a GAAP net loss of $29.3 million, or $0.87 per share, in the fourth quarter of 2016 compared with a GAAP net loss of $20.4 million, or $0.76 per share, in 2015’s final quarter, according to a company press release.Quarterly research and development expenses were $14.1 million while general administrative expenses totaled $14.7 million, compared with $12.3 million and $7.7 million, respectively, in the fourth quarter a year ago.